Pharma player Hetero Group on Monday said it has emerged as the first in the world to receive the World Health Organisation’s prequalification of medicines programme (WHO-PQ) for its generic version of Covid-19 oral antiviral treatment candidate Nirmatrelvir, which along with Ritonavir is used as part of Pfizer’s Paxlovid.
